A New Chapter for AIIMS Delhi: NITI Aayog Plans Structural Overhaul

IMT News Desk
IMT News Desk
· 2 min read
Wide view of the Palace of the Parliament in Bucharest, Romania. Garden in front of it

NITI Aayog is preparing a roadmap to transform AIIMS Delhi’s operations, patient care and infrastructure to meet international healthcare standards.

A government-led committee headed by Dr. VK Paul, Member of NITI Aayog, is working on a proposal that could reshape the future of AIIMS Delhi. With rising patient volumes and infrastructure strain, the All India Institute of Medical Sciences is set to undergo a major transformation. The committee is tasked with drafting a detailed reform plan, backed by implementation timelines, to upgrade the institution’s systems and align them with global benchmarks.

According to an ET Report, at the heart of the proposal lies a plan to reduce patient load at AIIMS’ main campus by expanding its clinical services across the National Capital Region. This move would allow AIIMS to focus primarily on trauma care and complex medical cases, while routine outpatient services could be handled at satellite centers. Every day, AIIMS sees close to 7,200 patients in its outpatient department and about 500 in the emergency wing. The growing numbers have long outpaced its existing capacity, leading to delays and limited research opportunities for its medical faculty.

The committee is exploring ways to use existing infrastructure in underutilised government hospitals and even private facilities to host extended OPDs of AIIMS. This decentralised model, if implemented with strict oversight, could ease congestion and ensure more focused care across the region. Experts involved in stakeholder discussions believe that decentralisation will only succeed if supported by consistent quality control and transparent governance.

Beyond infrastructure, the committee’s mandate also includes evaluating internal processes, hospital governance and medical education. The outcome of this exercise will be presented to the health ministry later this year. The recommendations will span short, medium, and long-term changes, addressing both service delivery and institutional governance.

The government sees this reform as critical not just for AIIMS Delhi, but for setting a model of advanced tertiary care across India. By making space for research, training, and improved patient handling, the goal is to preserve AIIMS’ role as a leader in Indian public healthcare while preparing it for the demands of the future.

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk